Introduction {#S8}
============

Understanding the risks associated with the COVID-19 pandemic^[@R1]^ on healthcare workers (HCW), including the risk of acquisition at work vs other settings, is crucial. Prediction of risk can inform how to protect HCWs such as recommendations on use of personal protective equipment (PPE) at work or in the community. The presence of specific symptoms in HCW (China, US)^[@R2],[@R3]^ and symptoms predicting SARS-CoV-2 test positivity in HCW (Netherlands)^[@R4]^ have been reported as well as characteristics associated with HCW deaths (China).^[@R5]^ Based upon data from the 2018 National Health Interview Survey, it was estimated that 26.6% of patient facing HCW were at increased risk for poor outcomes from COVID-19 infection because of their comorbidities or age.^[@R6]^ Reported experiences in China^[@R7]^, Italy^[@R8]^ and Solano County, CA without initial use of PPE^[@R9]^ showed higher percentages of HCW testing positive for COVID-19. In contrast, a screening study of HCW in England showed no significant difference in positive results between clinical and nonclinical staff with implementation of isolation and PPE protocols perhaps suggesting predominant community rather than nosocomial transmission patterns.^[@R10]^ The extent of risk modification with PPE remains unclear.^[@R7]--[@R9],[@R11]^ A recent prospective study in the United Kingdom and US suggested a five-fold increased risk for HCW caring for patients with COVID-19 compared to HCW not caring for patients with COVID-19, even with the use of PPE^[@R12]^ while another study of HCW in a large healthcare system showed a decrease in positive tests for SARS-CoV-2 associated with a universal masking recommendation.^[@R13]^ This heterogeneous landscape makes it difficult for the HCW community to determine actual risk of acquiring COVID-19 in healthcare vs. community settings and the effectiveness of various risk-mitigating strategies.

The Cleveland Clinic Health System (CCHS) is a large, integrated health system with 55,574 eligible employees in Ohio & Florida. The CCHS initiated multiple COVID-19 related public health initiatives to mitigate the spread of the disease and its impact on the HCW community. In parallel, we maintained a rigorous, comprehensive, and prospective registry capturing disease risk and progression in all individuals tested for COVID-19 in our health system. In this study, we aimed to assess whether HCW are at higher risk for COVID-19 infection, COVID-19 related hospitalization, and intensive care unit (ICU) admission compared to non-HCW using advanced statistical methodology to account for various confounders.

Methods {#S9}
=======

Cohort definition {#S10}
-----------------

### COVID-19 Cleveland clinic enterprise registry. {#S11}

All patients, regardless of age, who were tested for COVID-19 at all CCHS locations in Ohio and Florida were included in this research registry. For this study, all individuals who were tested for COVID-19 in the CCHS between March 8, 2020 and June 9, 2020 were studied. This registry provides better representation of the overall population than testing restricted to one geographic health system site. Registry variables were chosen to reflect available literature on COVID-19 disease characterization, progression, and proposed treatments, including medications initially thought to have potential for benefit after drug-repurposing network analysis.^[@R14]^ Capture of detailed research data was facilitated by the creation of standardized clinical templates implemented across the healthcare system as patients were seeking care for COVID-19-related concerns. Data were extracted via previously validated automated feeds from electronic health records^[@R15]^ (EPIC; EPIC Systems Corporation) and manually by a study team trained on uniform sources for the study variables. Study data were collected and managed using REDCap electronic data capture tools hosted at the Cleveland Clinic.^[@R16],[@R17]^ The COVID-19 Research Registry team includes a "Reviewer" group and a "Quality Assurance" group. The reviewers were responsible for manually abstracting and entering a subset of variables that cannot be automatically extracted from the electronic health record (EHR). Reviewers were also asked to verify high-priority variables that have been automatically pulled into the database from EPIC. The Cleveland Clinic Institutional Review Board approved this study and waived the requirements for written informed consent.

### Identification o f HCW. {#S12}

Individuals were identified as HCW through CCHS Occupational Health and their job description was identified as having direct contact with patients or "patient-facing" vs. non-patient facing based upon the listing in the CCHS Human Resources database.

Public health and employer-initiated risk mitigation measures {#S13}
-------------------------------------------------------------

Public health guidelines for CCHS employees and availability of testing for COVID-19 changed rapidly between 3/6/2020--4/24/2020 ([Appendix 1](#SD1){ref-type="supplementary-material"}), the most relevant being the *recommendation* for universal masking for CCHS employees on 4/7/2020 and *requirement* on 4/24/2020. Regarding state public health orders, a stay at home order was issued in Ohio on 3/22/2020 with phased re-opening in May starting with restaurants and bars on 5/14/2020^[@R18]^ and in Florida a public health advisory was issued on 3/25/2020 addressing vulnerable populations, private gatherings, and workforce density^[@R19]^ with reopening beginning on 5/18/2020.^[@R20]^

Statistical Analysis {#S14}
--------------------

All descriptive statistics were reported as counts (percentages) or median (interquartile ranges \[IQRs\]). For comparison of demographic variables and comorbidities among cohorts, Wilcoxon signed-rank tests were used for numeric variables, while χ^2^ or Fisher exact tests were used for categorical variables. To address differences in baseline characteristics of non-HCW and HCW, specifically as related to underlying comorbidities, and the limitations of current literature that failed to account for such differences, we leveraged appropriate statistical methodology to study our research questions. Overlap propensity score^[@R21],[@R22]^ weighting was performed to address potential confounding in comparing HCW to non-HCW given their baseline differences. The overlap propensity score weighting method was chosen given its benefits of preservation of numbers of individuals in each group and of achieving higher levels of precision in the resulting estimates. This methodology is preferred when the propensity score distributions among the groups are dissimilar and when the propensity scores are clustered near the extremes (i.e. close to zero or one). A propensity score for being a HCW was estimated from a multivariable logistic regression model. For the outcome of being test positive for COVID-19, the propensity score logistic regression model included covariates that were found to be associated with a positive COVID-19 test outcome in our previous work.^[@R23]^ For the outcomes of hospital and intensive care unit (ICU) admission of COVID-19 test positive patients, the propensity score covariates are those that were found associated with COVID-19 hospitalization outcome in our previous work including age, race, ethnicity, gender, smoking history, body mass index, median income, population per housing unit, presenting symptoms (including fever, fatigue, shortness of breath, diarrhea, vomiting), comorbidities (including asthma, hypertension, diabetes, immunosuppressive disease), medications (including immunosuppressive treatment, non-steroidal anti-inflammatory drugs \[NSAIDs\]), and laboratory values (including pre-testing platelets, aspartate aminotransferase, blood urea nitrogen, chloride, and potassium).

The overlap propensity score weighting method was then applied where each patient's statistical weight is the probability of that patient being assigned to the opposite group.^[@R21]^ Overlap propensity score weighted logistic regression models were used to investigate associations between HCW status and the probability of testing positive for SARS-CoV-2, hospital admission for COVID-19 and ICU admission for COVID-19 illness. The results are thus reported as weighted proportions, odds ratios and 95% confidence intervals. All statistical analyses were performed using R 3.5 and SAS version 9.4 (SAS Institute). *P* values were 2-sided, with a significance threshold of .05.

We then used locally weighted regression smoother (LOESS) to summarize the trend of COVID-19 test positivity through the study period for HCW and non-HCW as related to the public health measures instituted at the state level in Ohio and those specific to the CCHS.

Results {#S15}
=======

 {#S16}

### Overall tested cohort characteristics. {#S17}

Of the 72,909 individuals tested for COVID-19 in the CCHS Research Registry, there were 6,145 HCW and 66,764 non-HCW with over 90% of HCW and 75% of non-HCW tested from Ohio. There were 9% of HCW who tested positive for COVID-19 compared to 6.5% of non-HCW, p\<0.001 ([Table 1](#T1){ref-type="table"}). The HCW tested were younger than non-HCW (median age 39.7 vs. 57.5, p\<0.001) with more females (proportion of males 21.5 vs. 44.9%, p\<0.001), higher proportion of Asian and lower proportion of Black persons (3.4 vs. 1.0% and 16.2 vs. 18.3%, respectively, p\<0.001), higher proportion identifying as non-Hispanic (90.8 vs. 87.6%, p \<0.001), higher median income, and higher proportion of non-smokers. The neighborhood characteristics of population density as measured per square kilometer was similar for tested HCW vs. non- HCW while the population per housing unit was slightly higher. The HCW were more likely to report an exposure to COVID-19 (72.0% vs. 17.0%, p\<0.001) and also to report having a family member with COVID-19 (28.3 vs. 14.2%, p 0.005). Regarding presenting symptoms, a slightly higher proportion of HCW reported cough (32.0 vs. 29.6%, p 0.001), a lower proportion reported fever (15.0 vs. 19.5%, p \<0.001) or shortness of breath (14.6 vs. 25.7%, p\<0.001), while a higher proportion reported diarrhea (11.9 vs. 9.5%, p\<0.001) and lower proportion reported vomiting (7.4 vs. 9.7%, p \<0.001). Of note, the tested HCW were, in general, healthier than the non-HCW group. The HCW had a lower proportion of several comorbidities including chronic obstructive pulmonary disease(COPD)/emphysema, diabetes, hypertension, coronary artery disease, heart failure, cancer, history of transplant, or immunosuppressive disease and were more likely to have received the influenza vaccine (85.9 vs. 45.4%, p \<0.001). The HCW tested had a lower proportion of previous prescriptions for immunosuppressive treatment, NSAIDs, steroids, carvedilol, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or melatonin.

### COVID-19 cohort characteristics and outcomes: {#S18}

There were 551 HCW and 4,353 non-HCW who tested positive for COVID-19 ([Appendix Table 2](#SD1){ref-type="supplementary-material"}). Of those who tested positive for COVID-19, a lower proportion of HCW were hospitalized compared to non-HCW (38 or 6.9% HCW vs. 1205 or 27.7% non-HCW) or were admitted to the intensive care unit (10 or 1.8% HCW vs. 470 or 10.8% non-HCW). In the group who tested positive for COVID-19, there was a greater proportion of HCW of Asian and White race compared to non-HCW (2.9 vs. 0.8% and 61.0 vs 56.4%, respectively), a similar proportion of HCW with a positive COVID-19 test had presenting symptoms of cough, fatigue, diarrhea, loss of appetite, and vomiting and a lower proportion had fever or shortness of breath. Lower proportions of HCW testing positive had COPD/emphysema, diabetes, coronary artery disease, heart failure, cancer, or immunosuppressive disease and were previously prescribed carvedilol, angiotensin converting enzyme inhibitors, angiotensin receptor blockers or melatonin compared to non-HCW. The neighborhood population characteristics of population density or population per housing unit did not differ for those HCW who tested positive and median income was slightly higher compared to non-HCW.

### Overlap propensity weighting: {#S19}

Using the variables in the prediction model for COVID-19 test positivity,^[@R23]^ overlap propensity score weighting ([Table 2](#T2){ref-type="table"}) resulted in propensity score weighted proportions of 7.7 vs. 8.9 for non-HCW vs. HCW having a positive test and produced an overlap propensity score weighted odds ratio of 1.17 with a 95% confidence interval (CI) of 0.99--1.38 for a HCW having a positive test compared to a non-HCW ([Figure 1 a](#F1){ref-type="fig"}). Then using the variables which predicted hospitalization for COVID-19 infection, overlap propensity score weighting was applied ([Table 3](#T3){ref-type="table"}) with weighted proportions for being hospitalized 15.9 vs. 7.4 for non-HCW vs. HCW, an odds ratio of 0.42 (CI 0.26 −0.66) for a HCW being hospitalized for COVID-19 compared to a non-HCW. For ICU admission, weighted proportions were 4.5 vs.2.2 for non-HCW vs. HCW with an odds ratio of 0.48 (CI 0.20--1.04) for HCW being admitted to the ICU compared to non-HCW ([Figure 1 a](#F1){ref-type="fig"}).

Subgroup analysis {#S20}
-----------------

We then compared characteristics of HCW identified as having positions that required direct contact with patients ("patient facing") and those that did not. There were 5,159 HCW with patient-facing positions and 986 HCW in non-patient facing roles ([Appendix Table 3](#SD1){ref-type="supplementary-material"}). The HCW with patient-facing roles were younger (median age 38 vs. 47 years, p\<0.001), with more females (proportion males 20.6 vs. 26.2%, p \<0.001), lower proportion of Black race and higher Asian race, and with greater proportion reporting exposure to COVID-19 (73.7 vs. 62.9%, p \< 0.001). The patient-facing HCW had lower proportions presenting with fatigue or shortness of breath and higher proportion with loss of appetite. There were no significant differences in laboratory values upon presentation. The patient-facing HCW had lower proportions of some previously prescribed medications including NSAIDs, steroids, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and melatonin. The patient-facing HCW group had lower proportions of comorbidities including COPD/emphysema, diabetes, hypertension, coronary artery disease, cancer, connective tissue disease, and immunosuppressive disease. Applying the overlap propensity score weighting ([Appendix Tables 4](#SD1){ref-type="supplementary-material"}, [5](#SD1){ref-type="supplementary-material"}; [Figure 1 b](#F1){ref-type="fig"}) showed patient-facing HCW with increased odds of having a positive SARS-CoV-2 test result (OR 1.60, CI 1.08--2.39, weighted proportions 8.6 vs. 5.5), and lower but non-significant odds of hospital admission (OR 0.88, CI 0.20--3.66, proportions10.2 vs. 11.4) and ICU admission (OR 0.34, CI 0.01--3.97, proportions 1.8 vs. 5.2).

Temporal relationship between disease prevention measures and positive tests {#S21}
----------------------------------------------------------------------------

The summary of the trend of SARS-CoV-2 positive test results in the study period is shown in [Figure 2](#F2){ref-type="fig"}. The overall proportion of positive COVID-19 test results decreased during the study period and the trend for HCW and followed that of non-HCW.

Discussion {#S22}
==========

Our analysis of HCW compared to non-HCW who were tested for SARS-CoV-2 in one health system with 2 geographic locations (Ohio, Florida), and which controlled for significant differences in baseline characteristics between the HCW and non-HCW groups, showed that the odds of having a positive COVID-19 test were not significantly different for HCW compared to non-HCW, and HCW had lower odds of subsequent hospitalization, and without statistically significant differences in ICU admission compared to non-HCW once they tested positive. The HCW classified as having patient-facing positions had higher and significant odds of a positive COVID-19 test with insignificant differences detected compared to non-patient facing HCW in outcomes of hospitalization or ICU admission. We found a similar proportion of HCW with a positive COVID-19 test had presenting symptoms of cough, fatigue, diarrhea, loss of appetite, and vomiting while a lower proportion had fever or shortness of breath. We note that we were not able to capture the symptoms of loss of taste and/or smell and that these symptoms may be common especially with mild cases of COVID-19.^[@R24],[@R25]^

The overall proportion of COVID-19 positive tests in HCW was low and decreased during the study period corresponding with implementation of risk-mitigation measures in our health system such as the recommendations for universal masking and physical distancing but also followed the trend for non-HCW. Several of the previous studies of HCW risk for infection during the COVID-19 pandemic were limited by their sample sizes, 7--9 lack of generalizability for healthcare systems that have adequate access to PPE,^[@R7]--[@R9]^ methodology relying on self-report,^[@R12]^ limited ability to adjust for known risk factors of disease susceptibility and progression^[@R7]--[@R10],[@R12]^ and lacking data to investigate the relative effects of dual exposure of HCW to COVID-19 in the community versus the workplace.^[@R7]--[@R10],[@R12]^ The fact that HCW identified as patient-facing had a significantly higher odds for SARS-CoV-2 test positivity suggests an increased risk of COVID-19 infection with work exposure. However, it is important to note in our study that that over 70% of the HCW group reported an exposure to COVID-19 with 28% reporting exposure to a family member with COVID-19. In our study, we were not able to confirm if the patient-facing HCW were working in patient-facing areas the 14-day period before the test was ordered when exposure could have occurred, or whether the exposure occurred with or without PPE - both in the workplace or in the community, or the relative contribution of initially prioritizing testing availability to HCW with reported exposures. While the risk to HCW attributed to community spread may not be captured in our available data, the reported exposure risk including the higher proportion of HCW vs. non-HCW reporting exposure to a family member with COVID-19 suggests a degree of community acquisition of infection. A potential contributing factor to community acquisition is that HCWs, particularly patient-facing HCW, are less able to follow stay-at-home guidelines or work remotely from home. Indeed, while PPE use is associated with decrease risk of infection from coronavirus,^[@R26]^ a recent report estimated less than 5% risk to HCW inadvertently exposed to patients not known to be SARS-CoV-2-positive at the time of initial exposure with exposure likely occurring without appropriate PPE^[@R27]^ suggesting that the work exposure risk may actually be low. However, universal pandemic precautions have been recommended for optimal risk mitigation for HCW.^[@R28]^

Conclusion {#S23}
==========

In our analysis of one healthcare system which implemented significant risk mitigation strategies to prevent the spread of COVID-19 infection, and which controlled for significant baseline differences in HCW compared to non-HCW, the odds for SARS-CoV-2 infection were similar for HCW and non-HCW and HCW had lower odds for COVID-19 related hospitalization. The patient facing HCW had higher odds of SARS-CoV-2 infection.
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###### 

Characteristics of All Patients Tested for SARS-CoV-2 by Health Care Worker (HCW) Status

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Non-HCW\                                    HCW\                                        p-value
                                                    Number(%) or MediantInterquaitile Range\]   Number(%) or Mediantlnterquartile Range\]   
  ------------------------------------------------- ------------------------------------------- ------------------------------------------- ---------
  **Number**                                        66764                                       6145                                        

  **SARS-CoV-2 Positive**                           4353 ( 6.5)                                 551 ( 9.0)                                  \<0.001

  **Demographics:**                                                                                                                         

  Location                                                                                                                                  \<0.001

  Ohio                                              50204 ( 75.2)                               5642 ( 91.8)                                

  Florida                                           13957 ( 20.9)                               503 ( 8.2)                                  

  Unknown                                           2603 ( 3.9)                                 0                                           

  Race                                                                                                                                      \<0.001

  Asian                                             672 ( 1.0)                                  206 ( 3.4)                                  

  Black                                             12201 ( 18.3)                               995 ( 16.2)                                 

  Other                                             5394 ( 8.1)                                 490 ( 8.0)                                  

  White                                             48497 ( 72.6)                               4454 ( 72.5)                                

  Male                                              29959 ( 44.9)                               1322 ( 21.5)                                \<0.001

  Non-Hispanic                                      58496 ( 87.6)                               5577 ( 90.8)                                \<0.001

  Smoking                                                                                                                                   \<0.001

  Current Smoker                                    9316 ( 14.0)                                147 ( 2.4)                                  

  Former Smoker                                     30196 ( 45.2)                               1737 ( 28.3)                                

  No                                                27048 ( 40.5)                               4259 ( 69.3)                                

  Unknown                                           204 ( 0.3)                                  2 ( 0.0)                                    

  Age                                               57.53 \[39.32, 70.26\]                      39.67 \[31.29, 51.80\]                      \<0.001

  **Exposure history:**                                                                                                                     

  Exposed to COVID-19                               11369 ( 17.0)                               4424 ( 72.0)                                \<0.001

  Family member with COVID-19                       9503 ( 14.2)                                1740 (28.3)                                 \<0.001

  **Presenting symptoms:**                                                                                                                  

  Cough                                             19744 ( 29.6)                               1968 ( 32.0)                                0.001

  Fever                                             12997 ( 19.5)                               922 ( 15.0)                                 \<0.001

  Fatigue                                           8020 ( 12.0)                                637 ( 10.4)                                 \<0.001

  Sputum production                                 402 ( 0.6)                                  45 ( 0.7)                                   0.244

  Flu-like symptoms                                 5949 ( 8.9)                                 423 ( 6.9)                                  \<0.001

  Shortness of breath                               17133 ( 25.7)                               898 ( 14.6)                                 \<0.001

  Diarrhea                                          6335 ( 9.5)                                 731 ( 11.9)                                 \<0.001

  Loss of appetite                                  1505 ( 2.3)                                 299 ( 4.9)                                  \<0.001

  Vomiting                                          6471 ( 9.7)                                 454 ( 7.4)                                  \<0.001

  **Co-morbidities:**                                                                                                                       

  Body Mass Index                                   28.37 \[25.85, 31.07\]                      28.37 \[27.37, 29.13\]                      \<0.001

  Chronic Obstructive Pulmonary Disease/emphysema   8247 ( 12.4)                                166 ( 2.7)                                  \<0.001

  Asthma                                            12057 ( 18.1)                               1343 ( 21.9)                                \<0.001

  Diabetes                                          13418 ( 20.1)                               428 ( 7.0)                                  \<0.001

  Hypertension                                      30727 ( 46.0)                               1505 ( 24.5)                                \<0.001

  Coronary artery disease                           10181 ( 15.2)                               204 ( 3.3)                                  \<0.001

  Heart failure                                     8192 ( 12.3)                                93 ( 1.5)                                   \<0.001

  Cancer                                            12469 ( 18.7)                               646 ( 10.5)                                 \<0.001

  Transplant history                                1120 ( 1.7)                                 19 ( 0.3)                                   \<0.001

  Multiple sclerosis                                493 ( 0.7)                                  43 ( 0.7)                                   0.794

  Connective tissue disease                         2376 ( 3.6)                                 178 ( 2.9)                                  0.008

  Inflammatory Bowel Disease                        1604 ( 2.4)                                 112 ( 1.8)                                  0.005

  Immunosuppressive disease                         10375 ( 15.5)                               414 ( 6.7)                                  \<0.001

  **Vaccination history:**                                                                                                                  

  Influenza vaccine                                 30340 ( 45.4)                               5277 ( 85.9)                                \<0.001

  Pneumococcal polysaccharide vaccine               17808 ( 26.7)                               451 ( 7.3)                                  \<0.001

  **Laboratory findings upon presentation:**                                                                                                

  Pre-testing platelets                             238.00 \[238.00, 238.00\]                   238.00 \[238.00, 238.00\]                   0.137

  Pre- testing AST                                  23.00 \[23.00, 23.00\]                      23.00 \[23.00, 23.00\]                      0.051

  Pre- testing BUN                                  16.00 \[16.00, 16.00\]                      16.00 \[16.00, 16.00\]                      \<0.001

  Pre- testing Chloride                             101.00 \[101.00, 101.00\]                   101.00 \[101.00, 101.00\]                   0.092

  Pre- testing Creatinine                           0.92 \[0.92, 0.92\]                         0.92 \[0.92, 0.92\]                         \<0.001

  Pre-testing hematocrit                            39.50 \[39.50, 39.50\]                      39.50 \[39.50, 39.50\]                      0.41

  Pre- testing Potassium                            4.10 \[4.10, 4.10\]                         4.10 \[4.10, 4.10\]                         0.081

  **Home medications:**                                                                                                                     

  Immunosuppressive treatment                       2392 (3.6)                                  270 ( 4.4)                                  \<0.001

  Nonsteroidal Anti-inflammatory Drugs              19651 ( 29.4)                               1048 ( 17.1)                                \<0.001

  Steroids                                          11838 ( 17.7)                               969 ( 15.8)                                 \<0.001

  Carvedilol                                        2803 ( 4.2)                                 40 ( 0.7)                                   \<0.001

  Angiotensin converting enzyme inhibitor           7568 ( 11.3)                                329 ( 5.4)                                  \<0.001

  Angiotensin receptor blocker                      5698 ( 8.5)                                 228 ( 3.7)                                  \<0.001

  Melatonin                                         3078 ( 4.6)                                 52 ( 0.8)                                   \<0.001

  **Social influencers of health:**                                                                                                         

  Population Per Square Kilometer                   3.03 \[2.63, 3.29\]                         3.01 \[2.64, 3.28\]                         0.568

  Median Income per \$1000                          58.09 \[41.62, 76.21\]                      64.78 \[49.78, 85.54\]                      \<0.001

  Population Per Housing Unit                       2.22 \[1.93, 2.49\]                         2.26 \[2.01, 2.51\]                         \<0.001
  ---------------------------------------------------------------------------------------------------------------------------------------------------

###### 

All tested patients: Overlap Propensity Score-Weighted Characteristics a a Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)

                                                    Non- HCW   HCW
  ------------------------------------------------- ---------- -------------------
  Count                                             66764      6145
  Race                                                         
  Asian                                             2.3        2.3
  Black                                             17.9       17.9
  Other                                             8          8
  White                                             71.8       71.8
  Male                                              25.1       25.1
  Non-Hispanic                                      90.2       90.2
  Smoking                                                      
  Current Smoker                                    3.7        3.7
  Former Smoker                                     31.7       31.7
  No                                                64.6       64.6
  Unknown                                           0          0
  Age                                               43.38      43.38
  Exposed to COVID-19                               58.1       58.1
  Family member with COVID-19                       0.1        0.1
  Cough                                             34.4       34.4
  Fever                                             18         18
  Fatigue                                           11.7       11.7
  Sputum production                                 0.9        0.9
  Flu-like symptoms                                 7.3        7.3
  Diarrhea                                          12.7       12.7
  Loss of appetite                                  4.3        4.3
  Vomiting                                          8.7        8.7
  Asthma                                            22.9       22.9
  Coronary artery disease                           4.6        4.6
  Transplant history                                0.5        0.5
  Connective tissue disease                         3.4        3.4
  Inflammatory Bowel Disease                        2.1        2.1
  Influenza vaccine                                 79.2       79.2
  Pneumococcal polysaccharide vaccine               11.3       11.3
  Pre-testing platelets                             240.05     240.05
  Pre- testing Aspartate Aminotransferase           23.87      23.87
  Pre- testing Chloride                             101.05     101.05
  Pre- testing Creatinine                           0.92       0.92
  Pre-testing Hematocrit                            39.48      39.48
  Pre- testing Potassium                            4.09       4.09
  Nonsteroidal Anti-inflammatory Drugs              20.4       20.4
  Steroids                                          17.4       17.4
  Carvedilol                                        0.9        0.9
  Angiotensin Converting Enzyme inhibitor           6.7        6.7
  Angiotensin Receptor Blocker                      4.9        4.9
  Melatonin                                         1.2        1.2
  Population Per Square Kilometer                   2.92       2.92
  Median Income (thousands of dollars)              68.20      68.20
  Body Mass Index                                   2.92       2.92
  **Final Result = Positive Test for SARS-CoV-2**   7.7        8.9
  **Odds Ratio (95% Confidence Interval)**                     1.17 (0.99, 1.38)

###### 

All test positive patients: Overlap Propensity Score--Weighted Characteristics^[a](#TFN1){ref-type="table-fn"}^

                                             Non-HCW   HCW
  ------------------------------------------ --------- -------------------
  Count                                      4353      551
  Race                                                 
  Asian                                      2.1       2.1
  Black                                      28.6      28.6
  Other                                      9.4       9.4
  White                                      59.9      59.9
  Male                                       30.7      30.7
  Ethnicity                                            
  Hispanic                                   3.3       3.3
  Non-Hispanic                               90.2      90.2
  Unknown                                    6.4       6.4
  Smoking                                              
  Current Smoker                             2.9       2.9
  Former Smoker                              18.6      18.6
  No                                         73.7      73.7
  Unknown                                    4.8       4.8
  Age                                        43.50     43.50
  Fever                                      44.8      44.8
  Fatigue                                    55.2      55.2
  Shortness of breath                        37        37
  Diarrhea                                   35        35
  Vomiting                                   24.7      24.7
  Asthma                                     12.6      12.6
  Diabetes                                   10.4      10.4
  Hypertension                               22.2      22.2
  Immunosuppressive treatment                6.9       6.9
  Immunosuppressive disease                  4.5       4.5
  Pre-testing platelets                      234.70    234.70
  Pre- testing Aspartate Aminotransferase    24.51     24.51
  Pre- testing Blood Urea Nitrogen           15.76     15.76
  Pre- testing Chloride                      100.04    100.04
  Pre- testing Potassium                     3.99      3.99
  Nonsteroidal Anti-inflammatory Drugs       17.4      17.4
  Median Income (thousands of dollars)       62.25     62.25
  Population Per Housing Unit                2.22      2.22
  Body Mass Index                            29.63     29.63
  **Final Result = Hospitalization**         15.9      7.4
  **Odds Ratio (95% Confidence Interval)**             0.42 (0.26, 0.66)
  **Intensive Care Unit Admission**          4.5       2.2
  **Odds Ratio (95% Confidence Interval)**             0.48 (0.20, 1.04)

Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)
